Seaport Therapeutics set terms this week for a $201 million initial public offering, the first neuropsychiatric-focused biotech to attempt a nine-figure U.S. listing since mid-2023. Pricing is scheduled before Friday's close. The company is offering 11.8 million shares at $16 to $18, a range that values the business at roughly $970 million post-money if the midpoint clears.
Seaport is a Boston spinout building a pipeline around CNS disorders — major depressive disorder, post-traumatic stress, Huntington's chorea. Lead asset STP-369, a GABA-A modulator, entered Phase II trials in September 2024. Second program STP-939 targets Huntington's with a kynurenine pathway inhibitor, Phase I data due mid-year. The company has no revenue, burned $63 million in the nine months through September, and carries $18 million cash on the balance sheet. The raise puts eighteen months of runway on the books if burn stays flat.
This matters because life-science IPOs vanished after the Fed's first 75-basis-point hike in June 2022. Biotech indices fell 41 percent peak-to-trough through October 2023, and the primary market stayed shut even as indices recovered 28 percent off the lows in 2024. Seaport is testing whether institutional demand has returned for clinical-stage neuroscience, a category that historically required twice the cash and twice the time of oncology programs. If the deal prices at or above midpoint, it signals that long-duration science plays are back in favor with crossover funds. If it prices below $16 or pulls, the window is still closed for anything without Phase III data.
The timing is deliberate. Seaport filed confidentially in October, amended publicly in December, and timed pricing for a week when the S&P Biotech ETF (XBI) sits 11 percent above its 200-day moving average and the NASDAQ Biotech Index just posted its best January in three years. Underwriters are J.P. Morgan, Jefferies, and Leerink — the same trio that priced Vor Biopharma at $16 in February 2021, a deal that now trades at $2.80. Seaport's backers include OrbiMed, Nextech, and Deerfield, three shops that have been trapped in late-stage privates for twenty-four months. They are taking liquidity at a 1.4x step-up from the last preferred round in Q2 2023, a modest return that reflects desperation more than conviction.
Watch whether the deal closes inside the range, and whether trading volume on day two holds above 3 million shares. If it does, expect two or three more neuroscience IPOs to file before March, likely from the same venture syndicates. If Seaport breaks issue within ten days, the window closes again and late-stage CNS companies go back to inside rounds at flat or down valuations. Also watch STP-369 Phase II interim data, due April. A clean readout moves the stock; a messy one confirms that the market priced in binary risk at 60 cents on the dollar.
The real tell is how much of the book comes from crossover funds versus biotech specialists. If Fidelity, T. Rowe, or Wellington show up in the next 13F, the life-science IPO market is back. If the register is all Perceptive, RTW, and RA Capital, this was a syndicate rescue dressed as a public offering.
The takeaway
First $200M+ neuro IPO in eighteen months tests whether institutional buyers will pay for Phase II CNS risk again.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.